Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) was submitted on February 24, 2022, reporting an event that occurred on February 18, 2022. The filing addresses the Company's obligations under the Contingent Value Rights (CVR) Agreement related to the 2019 acquisition of Celgene Corporation, specifically concerning the oncology product Abraxane.
Key Financial Metrics
- Abraxane Net Sales (FY 2021): $1,181,043,283
- Net Sales Payment to Trustee: Approximately $4,526,082
- Payout per CVR: Approximately $0.104592
- Payment Date: On or before March 7, 2022
The filing does not provide comprehensive revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company as a whole, as this report is limited to a specific contingent payment event.
Material Changes
This filing reports a specific contractual payment triggered by the net sales performance of Abraxane for the year ended December 31, 2021. It does not detail material changes to the Company's overall financial position or operations compared to prior periods, other than the execution of this specific CVR obligation.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of general risks. The primary contingency addressed is the fulfillment of the CVR Agreement payment based on the recorded 2021 net sales of Abraxane. The payment is scheduled to be distributed pro rata to holders of record as of March 6, 2022.
Key Facts for Investor Verification
- Verify the record date for CVR holders is March 6, 2022.
- Confirm the payment of approximately $0.104592 per CVR is processed by March 7, 2022.
- Note that the $1.18 billion Abraxane sales figure is the basis for the $4.5 million payment obligation.
- Understand that this filing does not reflect the Company's full annual financial results.